Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0H1EA
|
||||
Former ID |
DNCL002271
|
||||
Drug Name |
TH-302
|
||||
Drug Type |
Small molecular drug
|
||||
Company |
Threshold Pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C9H16Br2N5O4P
|
||||
InChI |
InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)
|
||||
InChIKey |
UGJWRPJDTDGERK-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Human DNA | Target Info | Modulator | ||
References | |||||
Ref 523562 | ClinicalTrials.gov (NCT01403610) Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab. U.S. National Institutes of Health. | ||||
Ref 543252 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8695). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.